GSK extend evaluation of FibroSelect purification technology

logo200

London, UK – 5 December 2016 – Puridify Limited (“Puridify”), developers of novel bioprocessing purification technologies for industrial biomolecule manufacture, today announced the signing of an 18 month collaboration with GlaxoSmithKline (“GSK”) to extend the evaluation of Puridify’s FibroSelect purification technology with a view to building a package to support potential use of nanofibres in toxicology and clinical manufacture.

Read more…

Puridify named as finalist for two prestigious bioprocess industry awards at BPI

London, UK – 30 September 2016 – Puridify Limited (“Puridify”), developers of novel bioprocessing purification technologies for industrial biomolecule manufacture, has been announced as a finalist for two BioProcess International Awards. These prestigious industry awards recognize the outstanding people, organizations, and technologies that define excellence and that have changed the status-quo by enabling more effective, less expensive biotherapeutic development and manufacturing.

Read more…

Mar 2016: Puridify establishes Scientific Advisory Board

London, UK – 07 March 2016 Puridify Limited (“Puridify”), developers of novel bioprocessing purification technologies for industrial biomolecule manufacture, today announced the establishment of a Scientific Advisory Board (SAB). The SAB comprises world-renowned key opinion leaders in the field of biotherapeutic manufacturing, with a wealth of experience covering both the academic and industrial setting.

The SAB comprises the following members:

Barry Buckland

Jan 2016: Puridify awarded Industrial Biotechnology Catalyst project

innovate-uk-logoInnovateUK CatalystUCLEPSRCBBSRC

Puridify was successful in leading this application for a £1,757,129 Industrial Research project from Innovate UK’s Industrial Biotechnology Catalyst program. This will see Puridify and University College London build on existing collaborations and feasibility data to develop new purification tools and strategies that can be applied across a range of next generation biotherapeutics to enable their cost effective manufacture delivering novel therapies to patients at an acceptable price for healthcare payers. This work is co-funded by the Engineering and Physical Sciences Research Council (EPSRC) and the Biotechnology and Biological Sciences Research Council (BBSRC).

Oct 2015: Puridify completes Series A funding for commercialisation of single-use nanofibre-based purification technology

Platform technology set to transform purification in bioprocess manufacturing

London, UK – 21 October 2015Puridify Limited (“Puridify”), developers of novel bioprocessing purification technologies for industrial biomolecule manufacture, today announced the closing of a £2.2 million Series A funding round. This follow-on investment by existing investors Imperial Innovations, SR One and UCL Business, brings the total raised including grant funding to £8 million, and is a strong expression of confidence in the company and the progress of its proprietary nanofibre purification platform, FibroSelect.

Read more…